Shares of Dexcom (NASDAQ:DXCM), a medical device company specializing in glucose monitoring systems, saw a significant increase of 5% following the announcement of its 2025 revenue forecast.
The company preannounced fourth-quarter sales that exceeded expectations, reporting $1.113 billion compared to the Street's anticipation of $1.096 billion.
Looking ahead, Dexcom set its 2025 guidance with projected sales of $4.6 billion, gross margins around 64.5%, and operating margins approximately 21%.
The 2025 revenue forecast aligns with current market expectations, indicating confidence in the company's strategic direction and operational targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.